sellWeak cluster of 210b5-1 plan
Patrick A Mayes sold $5.7M of INCY
EVP & Chief Scientific Officer at INCYTE CORP. 47,954 shares at an average of $119.58, traded Jul 31, 2026, filed Aug 4, 2026.
Warning score
23Value
$5.7M
47,954 shares
Holdings after
61,441
-46% from before
From 52-week low
+60%
low $74.89, close $119.52
From 52-week high
-8%
high $129.93, as of Jul 31, 2026
Score components
- +15RoleOfficer
- +25Trade size$5.7M at market
- +10Share of holdings soldSold 46% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
INCYOct 12, 2026 · close 111.36
Since filing Aug 4, 2026: -7.7%SPY +1.1% · excess -8.8%
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002079962-26-000013, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | MOption exercise Common Stock10b5-1 | +2,918 | $61.18 | $179k | 66,546 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Common Stock10b5-1 | +2,284 | $64.25 | $147k | 68,830 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Common Stock10b5-1 | +2,709 | $61.76 | $167k | 71,539 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Common Stock10b5-1 | +3,148 | $68.62 | $216k | 74,687 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Common Stock10b5-1 | +2,072 | $71.93 | $149k | 76,759 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Common Stock10b5-1 | +9,459 | $72.27 | $684k | 86,218 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Common Stock10b5-1 | +2,623 | $74.78 | $196k | 88,841 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Common Stock10b5-1 | +2,864 | $77.67 | $222k | 91,705 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Common Stock10b5-1 | +1,643 | $80.50 | $132k | 93,348 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Common Stock10b5-1 | +3,023 | $83.20 | $252k | 96,371 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Common Stock10b5-1 | +2,623 | $83.58 | $219k | 98,994 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Common Stock10b5-1 | +1,642 | $85.01 | $140k | 100,636 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Common Stock10b5-1 | +2,293 | $90.56 | $208k | 102,929 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Common Stock10b5-1 | +85 | $106.47 | $9,050 | 103,014 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Common Stock10b5-1 | +326 | $105.43 | $34k | 103,340 | Aug 4, 2026 |
| Jul 31, 2026 | SOpen-market sale Common Stock10b5-1 | -14,661 | $119.46 | $1.8M | 88,679 | Aug 4, 2026 |
| Jul 31, 2026 | SOpen-market sale Common Stock10b5-1 | -5,332 | $119.42 | $637k | 83,347 | Aug 4, 2026 |
| Jul 31, 2026 | SOpen-market sale Common Stock10b5-1 | -2,187 | $119.47 | $261k | 81,160 | Aug 4, 2026 |
| Jul 31, 2026 | SOpen-market sale Common Stock10b5-1 | -6,171 | $119.43 | $737k | 74,989 | Aug 4, 2026 |
| Jul 31, 2026 | SOpen-market sale Common Stock10b5-1 | -4,695 | $119.39 | $561k | 70,294 | Aug 4, 2026 |
| Jul 31, 2026 | SOpen-market sale Common Stock10b5-1 | -2,864 | $119.40 | $342k | 67,430 | Aug 4, 2026 |
| Jul 31, 2026 | SOpen-market sale Common Stock10b5-1 | -1,643 | $119.51 | $196k | 65,787 | Aug 4, 2026 |
| Jul 31, 2026 | SOpen-market sale Common Stock10b5-1 | -1,642 | $119.38 | $196k | 64,145 | Aug 4, 2026 |
| Jul 31, 2026 | SOpen-market sale Common Stock10b5-1 | -85 | $122.19 | $10k | 64,060 | Aug 4, 2026 |
| Jul 31, 2026 | SOpen-market sale Common Stock10b5-1 | -326 | $121.69 | $40k | 63,734 | Aug 4, 2026 |
| Jul 31, 2026 | SOpen-market sale Common Stock10b5-1 | -2,293 | $119.41 | $274k | 61,441 | Aug 4, 2026 |
| Aug 3, 2026 | MOption exercise Common Stock10b5-1 | +6,055 | $105.43 | $638k | 67,496 | Aug 4, 2026 |
| Aug 3, 2026 | SOpen-market sale Common Stock10b5-1 | -6,055 | $120.43 | $729k | 61,441 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,918 | $0.00 | $0 | 1,328 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,284 | $0.00 | $0 | 2,938 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,709 | $0.00 | $0 | 1,233 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -3,148 | $0.00 | $0 | 0 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,072 | $0.00 | $0 | 2,665 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -9,459 | $0.00 | $0 | 0 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,623 | $0.00 | $0 | 0 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,864 | $0.00 | $0 | 191 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -1,643 | $0.00 | $0 | 0 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -3,023 | $0.00 | $0 | 202 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,623 | $0.00 | $0 | 0 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -1,642 | $0.00 | $0 | 0 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,293 | $0.00 | $0 | 0 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -85 | $0.00 | $0 | 2,207 | Aug 4, 2026 |
| Jul 31, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -326 | $0.00 | $0 | 6,055 | Aug 4, 2026 |
| Aug 3, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -6,055 | $0.00 | $0 | 0 | Aug 4, 2026 |
Related signals
Other insiders at INCYTE CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | INCYTE CORP | Pablo J Cagnoni President, Global Head of R&D | $2.8M 23,218 shares | -11% | |
| 33Weak | INCYTE CORP | Pablo J Cagnoni President, Global Head of R&D | $1.4M 10,801 shares | -6% | |
| 33Weak | INCYTE CORP | Pablo J Cagnoni President, Global Head of R&D | $1.3M 10,803 shares | -5% | |
| 33Weak | INCYTE CORP | Pablo J Cagnoni President, Global Head of R&D | $1.3M 10,640 shares | -5% | |
| 1Weak | INCYTE CORP | Patrick A Mayes EVP & Chief Scientific Officer | $274k 2,207 shares | -3% | |
| 33Weak | INCYTE CORP | Pablo J Cagnoni President, Global Head of R&D | $1.9M 15,888 shares | -7% | |
| 15Weak | INCYTE CORP | Steven H Stein CMO & Head of Late-Stage Dev. | $215k 1,877 shares | -8% | |
| 14Weak | INCYTE CORP | Mohamed Khairie Issa EVP, Head of U.S. Commercial | $126k 1,093 shares | -2% | |
| 48Moderate | INCYTE CORP | Steven H Stein CMO & Head of Late-Stage Dev. | $3.2M 28,237 shares | -52% | |
| 0Weak | INCYTE CORP | Thomas Tray Principal Accounting Officer | $264k 2,639 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.